From the Editor: New Technologies: Not a Done Deal
For every test that has been accepted for use in clinical laboratories, scores of others have been dropped.
Read MorePosted by Jenny Lower | Apr 18, 2014 | Uncategorized |
For every test that has been accepted for use in clinical laboratories, scores of others have been dropped.
Read MorePosted by Jenny Lower | Apr 17, 2014 | Electrolytes, Uncategorized |
Founded in 2012 in La Jolla, Calif, Electrozyme is endeavoring to become the world leader in the development of printed electrochemical biosensors. The company offers a portfolio of printed biosensors that facilitate high-fidelity amperometric, voltammetric, and potentiometric electrochemical analyses of numerous compounds relevant to the healthcare, environmental sensing, and security monitoring domains.
Read MorePosted by Jenny Lower | Apr 17, 2014 | Cancer |
Menssana Research laboratories have established a new role for breath testing in the early detection of disease. Scientists there have developed a portable breath collection apparatus that can collect breath samples for highly sensitive laboratory analysis virtually anywhere.
Read MorePosted by Jenny Lower | Apr 17, 2014 | Cancer |
Technologies rarely advance at a steady and predictable pace, but new platforms and newer ideas are already shaping the future of clinical lab testing. This article from the April 2014 issue highlights a handful of companies that are working to bring new diagnostic technologies to market and improve patient care.
Read MorePosted by Steve Halasey | Apr 11, 2014 | Research |
Although most popular hospital urine pregnancy tests perform well in the first month after conception, a new study finds that many become significantly more likely to produce false-negative results after the fifth to seventh week of pregnancy.
Read More